Molecular structure of 4-(2-Chloroacetamido)benzoic acid, CAS Number: 4596-39-8
4-(2-Chloroacetamido)benzoic acid (CAS 4596-39-8)
CAS Number:
4596-39-8
Molecular Weight:
213.62
Molecular Formula:
C9H8ClNO3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
4-(2-Chloroacetamido)benzoic acid is a white crystalline powder classified as a benzoic acid derivative. It dissolves in ethanol, dimethylformamide, and pyridine but remains insoluble in chloroform, ether, and benzene. The compound′s ability to attach to proteins, particularly those found in blood, has made it valuable in scientific research. 4-(2-Chloroacetamido)benzoic acid has been used to investigate the binding characteristics of proteins with metal ions.
4-(2-Chloroacetamido)benzoic acid (CAS 4596-39-8) References
- Design, synthesis and glucose uptake activity of some novel glitazones. | Kar, K., et al. 2014. Bioorg Chem. 56: 27-33. PMID: 24927033
- 2-Mercaptobenzimidazole Schiff Bases: Design, Synthesis, Antimicrobial Studies and Anticancer Activity on HCT-116 Cell Line. | Tahlan, S., et al. 2019. Mini Rev Med Chem. 19: 1080-1092. PMID: 30306865
- Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. | Mohamed, MFA., et al. 2019. Bioorg Chem. 91: 103127. PMID: 31374527
- 4-(2-(1H-Benzo[d]imidazol-2-ylthio)acetamido)-N-(substituted phenyl)benzamides: design, synthesis and biological evaluation. | Tahlan, S., et al. 2019. BMC Chem. 13: 12. PMID: 31384761
- Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. | Eissa, IH., et al. 2019. Arch Pharm (Weinheim). 352: e1900123. PMID: 31463953
- Attenuating the Selection of Vancomycin Resistance Among Enterococci through the Development of Peptide-Based Vancomycin Antagonists. | Mull, RW., et al. 2020. ACS Infect Dis. 6: 2913-2925. PMID: 32946213
- Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. | Eissa, IH., et al. 2020. Bioorg Chem. 105: 104380. PMID: 33128967
- Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors. | El-Adl, K., et al. 2021. Bioorg Med Chem. 29: 115872. PMID: 33214036
- Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. | Alanazi, MM., et al. 2021. J Enzyme Inhib Med Chem. 36: 1760-1782. PMID: 34340610
- Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. | Khalifa, MM., et al. 2022. J Enzyme Inhib Med Chem. 37: 299-314. PMID: 34894955
- Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations. | Aziz, NAAM., et al. 2023. Arch Pharm (Weinheim). 356: e2200465. PMID: 36403198
- Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment. | Hanafy, NS., et al. 2023. Arch Pharm (Weinheim). 356: e2300137. PMID: 37147779
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
4-(2-Chloroacetamido)benzoic acid, 5 g | sc-232206 | 5 g | $70.00 |